Hospital General Medellín, Medellín, Colombia.
Hospital General Medellín, Medellín, Colombia; Department of Pediatrics, University of Antioquia, Medellín, Colombia.
Med Intensiva (Engl Ed). 2022 Feb;46(2):72-80. doi: 10.1016/j.medine.2020.09.009.
To compare the safety and effectiveness of Continuous Positive Airway Pressure (CPAP) vs. High Flow Nasal Cannula (HFNC) to prevent therapeutic failure and the need of invasive ventilation in children with acute moderate-severe bronchiolitis.
A systematic review and meta-analysis.
Medline, Embase, Lilacs, Cochrane and gray literature (May 2020) was performed.
Randomized clinical trials patients with moderate to severe bronchiolitis.
Therapeutic failure, need for invasive ventilation, adverse events, length of PCCU and of hospital stay.
The quality of the studies was assessed with the Cochrane risk and bias tool. We conducted meta-analysis using fixed effect model and random effects model.
Three RCTs were included. Showed less risk of therapeutic failure with CPAP compared with HFNC (RR=0.7; 95%CI 0.5-0.99) developed hours later in patients with CPAP (MD=3.16; 95%CI 1.55-4.77). We did not find differences in other outcomes, such as need of invasive ventilation (RR=0.60; 95%CI 0.25-1.43), apnea (RR=0.40; 95%CI 0.08-1.99), or number of days in the intensive care unit (MD=0.02; 95%CI -0.38 to 0.42), and length of hospitalization (MD=-1.00; 95%IC -2.66 to 0.66). Adverse events (skin lesions) were more common with CPAP (RR 2.47; 95%CI 1.17-5.22).
In moderate/severe bronchiolitis CPAP demonstrated a lower risk of therapeutic failure and a longer time to failure. But more adverse events like nasal injury. There were no differences in other variables.
比较持续气道正压通气(CPAP)与高流量鼻导管(HFNC)在预防小儿急性中重度毛细支气管炎治疗失败和需要有创通气方面的安全性和有效性。
系统评价和荟萃分析。
2020 年 5 月对 Medline、Embase、Lilacs、Cochrane 和灰色文献进行了检索。
中重度毛细支气管炎的随机临床试验患者。
治疗失败、有创通气需求、不良事件、PCCU 住院时间和住院时间。
使用 Cochrane 风险和偏倚工具评估研究质量。我们使用固定效应模型和随机效应模型进行荟萃分析。
纳入了 3 项 RCT。结果显示,CPAP 组治疗失败的风险低于 HFNC 组(RR=0.7;95%CI 0.5-0.99),CPAP 组的治疗失败发生在数小时后(MD=3.16;95%CI 1.55-4.77)。我们没有发现其他结果(如需要有创通气(RR=0.60;95%CI 0.25-1.43)、呼吸暂停(RR=0.40;95%CI 0.08-1.99)或重症监护病房天数(MD=0.02;95%CI -0.38 至 0.42)以及住院时间(MD=-1.00;95%IC -2.66 至 0.66))存在差异。CPAP 组的不良事件(皮肤损伤)更为常见(RR 2.47;95%CI 1.17-5.22)。
在中重度毛细支气管炎中,CPAP 显示出较低的治疗失败风险和较长的失败时间。但是有更多的不良事件,如鼻损伤。其他变量没有差异。